Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

StoneX Group clearly didn’t skip leg day—it just bulked up its Pfizer holdings by a massive 43.5% in Q4, scooping up over ...

The latest trading session saw Pfizer (PFE) ending at $24.70, denoting a +0.65% adjustment from its last day's close. This change lagged the S&P 500's 0.67% gain on the day. Meanwhile, the Dow ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $27.00.

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

While tariffs have triggered market volatility, certain pharmaceutical stocks still present strong investment opportunities.

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...